In 2021, Bushey led one of the most significant IPOs in the biotech sector, representing Century Therapeutics, a biotech innovator founded in 2019 to fight cancer. The aggregate gross proceeds from the offering, which closed in June 2021, were approximately $242.7 million.

Bushey also led a team advising Renovacor, an early stage biotechnology company pioneering AAV-based gene therapies for devastating cardiovascular and neurodegenerative diseases, on its combination with Chardan Healthcare Acquisition Corp, a SPAC, creating a newly formed merger subsidiary of CHAQ to be named “Renovacor, Inc.” Concurrently with the merger, certain investors provided an additional $30 million common stock private placement investment in public equity (PIPE) financing, also advised by Bushey and her team. The total deal value of $95.1 million includes the $30 million from the concurrent PIPE closing. The merger, new investors, and financing positioned Renovacor to advance its rare disease gene therapy program into phase I/II clinical trials. This transaction closed in September 2021.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]